HomeOur Focus AreasHIV & Hepatitis C

HIV & Hepatitis C

Overview:

HIV and AIDS remain important challenges to community health, in large part because HIV is concentrated in specific communities, and often in communities with a history of social exclusion and stigmatization.

After decades of research, we still have no cure. If AIDS has taught us anything, however, it is that no community is an island. Health threats to any part of our world are threats to us all. At the REACH lab, we see HIV as an epidemic that reveals the ongoing role of social stratification and exclusion in the making and breaking of disease.

Recent Blog Posts for HIV and Hepatitis C

In collaboration with El Punto en la Montaña, our syringe exchange partners in rural Puerto Rico, our team participated in

Duncan I., Curtis R., Reyes J.C., Abadie R., Khan B., Dombrowski, K. 2017. Hepatitis C serosorting among people who inject

Abadie, R., Welch-Lazoritz, M., Dombrowski, K., Khan, B. 2017. “Social Determinants of HIV/HCV Co-Infection: A case Study from PWID in

2016 Kirk Dombrowski, Bilal Khan, Patrick Habecker, Holly Hagan, Samuel R. Friedman, Mohammed Saad “The Interaction of Human Social Systems

2017 Melissa Welch-Lazoritz, Patrick Habecker, Kirk Dombrowski, Angelica Rivera Villegas, Carmen Ana Davila, Yadira Rolón Colón, Sandra Miranda De León,

A new article was published in the Philadelphia Inquirer that focuses on one of Puerto Rico's solutions to the heroin

Funded Projects

Our work with HIV and Hepatitis C research began with research involving agent-based simulation and modeling (“Injection Drug User Network Topologies and HIV Stabilization Dynamics” NIDA RC1 DA028476-01) and “Addressing HCV-related hepatocellular carcinoma: the current and future epidemics” PI Holly Hagan, NYU; NIDA R01 DA034637. More recently we began a field project in Puerto Rico that combines these techniques with original data collection (“Injection Risk Networks in Rural Puerto Rico” NIDA R01 DA037117. In addition, for the last decade we have worked closely with Samuel Friedman, Holly Hagan, and Sheri Deren of the Center for Drug Use and HIV Research in New York City (NIDA P30 DA011041).